13G Filing: Partner Fund Management and Pacira Pharmaceuticals Inc (PCRX)

Page 2 of 13

Page 2 of 13 – SEC Filing

CUSIP No. 695127100 13G Page
2 of 13 Pages

1.

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Partner Fund Management, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ¨

(b)x

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

0

6.

SHARED VOTING POWER

 

2,155,878 shares

7.

SOLE DISPOSITIVE POWER

0

8.

SHARED DISPOSITIVE POWER

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above

10.

CHECK BOX IF
THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES

¨

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.7%1

 

12.

TYPE OF REPORTING PERSON

IA; PN

11 The percentages reported in this Schedule 13G are based
upon 37,525,108 shares of common stock outstanding as of February 22, 2017 according to the Form 10-K filed by the issuer with
the Securities and Exchange Commission on March 1, 2017. All of the other numbers and percentages reported in this Schedule 13G
are as of 9:00 a.m. (ET) on the date of filing.

Follow Pacira Biosciences Inc. (NASDAQ:PCRX)

Page 2 of 13